Top

Naveen Pemmaraju, M.D.

Department of Leukemia, Division of Cancer Medicine

About Dr. Pemmaraju

After completing my Internal Medicine training at Johns Hopkins in the Osler Medical Program (2005-2008), I subsequently completed Hematology/Oncology training at MD Anderson Cancer Center Fellowship Program (MDACC; 2008-2011). I was selected as a Chief Fellow in my second year of fellowship training. I obtained ABIM board certification in Internal Medicine, Hematology and Oncology, and continued my career at MDACC as an Assistant Professor in the Department of Leukemia (start date 07/2011). In September 2017, I was promoted to Associate Professor in the Department of Leukemia. I maintain an active clinical schedule, during which I see patients 2-full days per week; including 2-months of inpatient service per year. I have fellow teaching responsibilities as the Leukemia Hematology/Oncology Course Director and was the sole recipient of the MDACC Gerald P. Bodey Award for Excellence in Education in 2020. I was recognized as our institution’s Faculty Educator of the Quarter in December 2022.

My clinical/translational research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Myeloproliferative Neoplasms (MPN) and Acute Myeloid Leukemia (AML). I have authored/co-authored over 265 publications in the medical literature (all available in PubMed). I have presented our group's work, as first author, in oral presentations at numerous national/international meetings: ASCO, ASH, EHA, AACR. Under the direct mentorship of Dr. Hagop Kantarjian, and Dr. Marina Konopleva, I have established our group's first, active, BPDCN clinic; which now serves as a worldwide referral base and has brought in many new patients to MDACC. This clinic continues to expand as one of the world’s most active BPDCN research programs with dedicated infrastructure and ample support for clinical and translational studies. For these efforts, I have been named MDACC’s, Department of Leukemia, Inaugural Director of BPDCN Program, in 2020. I am the PI/co-PI of many active clinical trials in the Leukemia department, for a translational sample study of patients with BPDCN, and was awarded a grant for identifying prognostic biomarkers in patients with BPDCN. I have developed key collaborative projects and lead groups in the areas BPDCN, MPN and AML, with clinical, hematopathology and dermatopathology teams; both internally and externally. I serve as our department’s Executive Director for the MDACC Network, helping to improve and expand upon leukemia and malignant hematology collaborations and clinical trials networking, and am an active member of the ASH Communications Committee, currently serving a 4-year term.

Meet Naveen Pemmaraju, M.D.

In the News

ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis

Medical illustration of healthy red platelets and cancerous white blood cells drifting along inside a pink-walled capillary

Understanding the types of leukemia

Reflections on caring for cancer patients during the COVID-19 pandemic

New blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment improves outlook for many patients

Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies

Cancerwise blog post: Naveen Pemmaraju, M.D., discusses acute myeloid leukemia (AML)

Acute myeloid leukemia: What to know

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2005	University of Arkansas for Medical Sciences, Little Rock, AR, USA, MD, Medicine
2001	Tulane University, New Orleans, LA, USA, BS, Cell and Molecular Biology

Postgraduate Training

2008-2011	Clinical Fellowship, Hematology and Medical Oncology, MD Anderson Cancer Center, Houston, TX
2005-2008	Clinical Residency, Internal Medicine, Johns Hopkins Hospital, Osler Internal Medicine Program, Baltimore, MD

Experience & Service

Academic Appointments

Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017

Administrative Appointments/Responsibilities

Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present

Course Director, Leukemia Rotation, Hematology/Oncology Fellowship Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present

Co-Chair, Leukemia Hematology Grand Rounds, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2021

Other Appointments/Responsibilities

Chief Fellow Housestaff Education, Hematology/Oncology, The University of Texas MD Anderson Cancer Center Fellowship Program, Houston, TX, 2009 - 2010

Institutional Committee Activities

Member, Clinical Research Committee (CRC), 2015 - 2021

Member, Pharmacy and Therapeutics Committee, 2013 - 2021

Member, Transfusion Committee, 2013 - 2016

Member, Clinical Competence Committee, 2013 - Present

Member, OncoLog Editorial Board, 2012 - 2017

Member, Fellowship Steering Committee, 2012 - Present

Member, Interviewing Committee, MD Anderson Hematology/Oncology Fellowship Program, 2010 - Present

Honors & Awards

2020	Gerald P. Bodey Award for Excellence in Education, The University of TX MD Anderson Cancer Center
2012	M. D. Anderson Apple Award for Excellence in Patient Education, The University of TX MD Anderson Cancer Center
2011	Merit Award, American Society of Clinical Oncology
2011	Advocacy Leadership Institute, American Society of Hematology
2010	Celgene 2010 Future Leaders Award for Clinical Research in Hematology, Celgene
2010	Jesse H. Jones Outstanding Teaching Fellow Award, The University of TX MD Anderson Cancer Center
2010	The Kimberly Patterson Fellowship in Leukemia Research, The University of TX MD Anderson Cancer Center
2005	H. Elvin Shuffield, MD Outstanding Medical Leadership Award, University of Arkansas for Medical Sciences
2005	Elected, Class President and Student Commencement Speaker, University of Arkansas for Medical Sciences
2004	Academic Scholarship, Arkansas Blood and Cancer Society
2004	Outstanding Geriatrics Medical Student, Junior Clerkship Award
2004	Academic Scholarship, Arkansas Medical Society Alliance AMA Foundation
2003	George Link Ackerman Academic Medical Scholarship, University of Arkansas for Medical Sciences
2002	Academic Medical Scholarship, Inaugural Class of 1957 UAMS Alumni
2000	Outstanding Peer Health Advocate of the Year, Student Crest Leadership Award

Professional Memberships

The American Society of Hematology (ASH) Committee on Communications, Washington, DC

Member, 2020 - 2023

Selected Publications

Peer-Reviewed Articles

Pemmaraju N, Garcia JS, Perkins A, Harb JG, Souers AJ, Werner ME, Brown CM, Passamonti F. New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-XL /BCL-2 inhibition with navitoclax. Cancer 129(22):3535-3545, 2023. e-Pub 2023. PMID: 37584267.
Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer 129(18):2828-2835, 2023. e-Pub 2023. PMID: 37243913.
Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, McCall D, Gibson A, Ragoonanan D, Petropoulos D, Tewari P, Nunez C, Mahadeo KM, Tasian SK, Lamble AJ, Pawlowska A, Hammond D, Maiti A, Haddad FG, Senapati J, Daver N, Gangat N, Konopleva M, Meshinchi S, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767-1778, 2023. e-Pub 2023. PMID: 37452102.
Pemmaraju N, Bose P, Rampal R, Gerds AT, Fleischman A, Verstovsek S. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy. Leuk Lymphoma 64(6):1-19, 2023. e-Pub 2023. PMID: 37081809.
Beird H, Yin CC, Khoury JD, Pierce S, Abbas HA, Zhao L, Skwarska A, Qazilbash M, Konopleva M, Futreal PA, Pemmaraju N. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv 7(10):2000-2003, 2023. e-Pub 2023. PMID: 36689729.
Pemmaraju N, Kantarjian H. Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clin Adv Hematol Oncol 21(5):257-264, 2023. PMID: 37145496.
Harrold E, Latham A, Pemmaraju N, Lieu CH. Early-Onset GI Cancers: Rising Trends, Genetic Risks, Novel Strategies, and Special Considerations. Am Soc Clin Oncol Educ Book 43:e398068, 2023. PMID: 37235819.
Babakhanlou R, Verstovsek S, Pemmaraju N, Rojas-Hernandez CM. Secondary erythrocytosis. Expert Rev Hematol 16(4):1-7, 2023. e-Pub 2023. PMID: 36927204.
Verstovsek S, Pemmaraju N, Reaven NL, Funk SE, Woody T, Valone F, Gupta S. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Ann Hematol 102(3):571-581, 2023. e-Pub 2023. PMID: 36637474.
Pemmaraju N, Kantarjian H, Sweet K, Wang E, Senapati J, Wilson NR, Konopleva M, Frankel AE, Gupta V, Mesa R, Ulrickson M, Gorak E, Bhatia S, Budak-Alpdogan T, Mason J, Garcia-Romero MT, Lopez-Santiago N, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran J, Fathi AT, Hall AC, Jacoby MA, Lancet J, Mannis G, Stein AS, Mims A, Rizzieri D, Olin R, Perl A, Schiller G, Shami P, Stone RM, Strickland S, Wieduwilt MJ, Daver N, Ravandi F, Vasu S, Guzman M, Roboz GJ, Khoury J, Qazilbash M, Aung PP, Cuglievan B, Madanat Y, Kharfan-Dabaja MA, Pawlowska A, Taylor J, Tallman M, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood 141(6):567-578, 2023. e-Pub 2022. PMID: 36399715.
Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):1-5, 2022. e-Pub 2022. PMID: 35787095.
Pemmaraju N, Harrison C, Gupta V, Verstovsek S, Scott B, Oh ST, Palandri F, Al-Ali HK, Sobas M, McMullin MF, Mesa R, Buckley S, Roman-Torres K, Vannucchi A, Yacoub A. Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis. EJHaem 3(4):1346-1351, 2022. e-Pub 2022. PMID: 36467816.
Mughal TI, Pemmaraju N, Bejar R, Gale RP, Bose P, Kiladjian JJ, Prchal J, Royston D, Pollyea D, Valent P, Brümmendorf TH, Skorski T, Patnaik M, Santini V, Fenaux P, Kucine N, Verstovsek S, Mesa R, Barbui T, Saglio G, Van Etten RA. Perspective Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies. Hematol Oncol 40(4):491-504, 2022. e-Pub 2022. PMID: 35368098.
Pemmaraju N, Wilson NR, Senapati J, Economides MP, Guzman ML, Neelapu SS, Kazemimood R, Davis RE, Jain N, Khoury JD, Sugita M, Cai T, Smith J, Frattini MG, Garton A, Roboz G, Konopleva M. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res 121:106928, 2022. e-Pub 2022. PMID: 35963025.
Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein AS, Meshinchi S, Mullen C, Angelucci E, Vinti L, Mughal TI, Pawlowska A. AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S244-S245, 2022. PMID: 36163828.
Pemmaraju N, Konopleva M, Sweet K, Stein A, Vasu S, Rizzieri D, Wang ES, Kantarjian H, Brooks C, Mughal T, Lane A. AML-465 Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm: Sub-Analysis of a Pivotal Trial by Age and Baseline Disease Involvement. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S254, 2022. PMID: 36163847.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334, 2022. PMID: 36164003.
Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-355 Patients With Prefibrotic Myelofibrosis and Inferior Outcome, a Single-Center Analysis. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334-S335, 2022. PMID: 36164004.
Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
Pemmaraju N, Sweet KL, Stein AS, Wang ES, Rizzieri DA, Vasu S, Rosenblat TL, Brooks CL, Habboubi N, Mughal TI, Kantarjian H, Konopleva M, Lane AA. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol 40(26):JCO2200034, 2022. e-Pub 2022. PMID: 35820082.
Wilson NR, Jain P, Gomez JA, Lu H, Pemmaraju N. Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndrome. Leuk Res 120:106909, 2022. e-Pub 2022. PMID: 35820269.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
Kim K, Bazinet A, Loghavi S, Konopleva M, Bhalla K, Daver N, Khoury JD, Kadia T, Wilson NR, Curry JL, Heberton M, Miller D, Pierce S, Borthakur G, Pemmaraju N. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res 119:106884, 2022. e-Pub 2022. PMID: 35691130.
Adimora IJ, Wilson NR, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics. Cancer 128(16):3019-3026, 2022. e-Pub 2022. PMID: 35726525.
Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, Oh ST, Passamonti F, Döhner K, Mead AJ. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer 128(13):2420-2432, 2022. e-Pub 2022. PMID: 35499819.
Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, Qin QQ, Tantravahi SK, Verstovsek S, Harrison C. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol 9(6):e434-e444, 2022. e-Pub 2022. PMID: 35576960.
Desikan SP, Ravandi F, Pemmaraju N, Konopleva M, Loghavi S, Jabbour EJ, Daver N, Jain N, Chien KS, Maiti A, Montalban-Bravo G, Kadia TM, Macaron W, DeLumpa R, Kwari M, Borthakur G, Short NJ. A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed or Refractory AML Harboring RAS Pathway-Activating Mutations. Acta Haematol. e-Pub 2022. PMID: 35717939.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Frontline HCVAD. Blood Adv 6(10):3027-3035, 2022. e-Pub 2022. PMID: 35061885.
Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol 40(15):JCO2102188, 2022. e-Pub 2022. PMID: 35180010.
Bôle-Richard E, Pemmaraju N, Caël B, Daguindau E, Lane AA. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 14(9), 2022. e-Pub 2022. PMID: 35565416.
Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, Kumar S, Scherber RM, Verstovsek S. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res 115:106809. e-Pub 2022. PMID: 35220060.
Gerds AT, Yu J, Scherber RM, Paranagama D, Kish JK, Visaria J, Singhal M, Verstovsek S, Pemmaraju N. Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes. Acta Haematol:1-5. e-Pub 2022. PMID: 35008087.
Wilson NR, Pemmaraju N. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opin Pharmacother:1-8. e-Pub 2022. PMID: 35060807.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. e-Pub 2022. PMID: 35077575.
Wilson NR, Bover L, Konopleva M, Han L, Neelapu S, Pemmaraju N. CD303 (BDCA-2) - a potential novel target for therapy in hematologic malignancies. Leuk Lymphoma 63(1):19-30, 2022. e-Pub 2021. PMID: 34486917.
Abla D, Abboud MR, Noun D, Tarek N, Pemmaraju N. Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review. Leuk Res Rep 17:100313, 2022. e-Pub 2022. PMID: 35462725.
Senapati J, Daver NG, Pemmaraju N. Antibody-Drug Conjugates in Myeloid Leukemias. Cancer J 28(6):454-461, 2022. PMID: 36383908.
Wilson NR, Pemmaraju N. How to Treat Adult Acute Myeloid Leukemia: An Evolving Paradigm. JACC CardioOncol 3(5):747-751, 2021. e-Pub 2021. PMID: 34988486.
Mouhayar EN, Hammond D, Lopez-Mattei J, Banchs J, Konopleva M, Pemmaraju N. Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome. JACC CardioOncol 3(5):752-755, 2021. e-Pub 2021. PMID: 34988487.
Gangat N, Konopleva M, Patnaik MM, Jabbour E, DiNardo C, Al-Kali A, Foran JM, Granroth GL, Olteanu H, Kadia T, Tefferi A, Pemmaraju N. Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. e-Pub 2021. PMID: 34807470.
Yin CC, Pemmaraju N, You MJ, Li S, Xu J, Wang W, Tang Z, Alswailmi O, Bhalla KN, Qazilbash MH, Konopleva M, Khoury JD. Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 13(23), 2021. e-Pub 2021. PMID: 34884997.
Wilson NR, Konopleva M, Khoury JD, Pemmaraju N. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. Clin Lymphoma Myeloma Leuk 21(11):734-740, 2021. e-Pub 2021. PMID: 34226167.
Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant. e-Pub 2021. PMID: 34629467.
DiPippo AJ, Wilson NR, Pemmaraju N. Targeting CD123 in BPDCN: an emerging field. Expert Rev Hematol:1-12. e-Pub 2021. PMID: 34607517.
Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. PMID: 34424319.
Lee SS, Verstovsek S, Pemmaraju N. Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy. J Immunother Precis Oncol 4(3):117-128, 2021. e-Pub 2021. PMID: 35663101.
El Hussein S, Wang SA, Pemmaraju N, Khoury JD, Loghavi S. Chronic Myelomonocytic Leukemia: Hematopathology Perspective. J Immunother Precis Oncol 4(3):142-149, 2021. e-Pub 2021. PMID: 35663104.
Pemmaraju N. Rare Blood Cancers in 2021: Importance of Continued Exchange of Ideas. J Immunother Precis Oncol 4(3):115-116, 2021. e-Pub 2021. PMID: 35663105.
El Hussein S, Wang W, Wang SA, Loghavi S, Wang X, Qiu L, Fang H, Medeiros LJ, Aung P, Torres Cabala C, Jorgensen JL, Pemmaraju N, Khoury JD. Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leuk Lymphoma:1-4. e-Pub 2021. PMID: 34304666.
Pemmaraju N, Wilson NR, Khoury JD, Jain N, Daver NG, Pierce SR, Jabbour EJ, Kadia TM, DiNardo CD, Garcia-Manero G, Qazilbash MH, Konopleva MY, Kantarjian HM. Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood. e-Pub 2021. PMID: 34098573.
Saxena K, Herbrich SM, Pemmaraju N, Kadia TM, DiNardo CD, Borthakur G, Pierce SA, Jabbour E, Wang SA, Bueso-Ramos C, Loghavi S, Tang G, Cheung CM, Alexander L, Kornblau S, Andreeff M, Garcia-Manero G, Ravandi F, Konopleva MY, Daver N. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer. e-Pub 2021. PMID: 34171128.
Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk 21(5):318-327.e6, 2021. e-Pub 2021. PMID: 33551345.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 18(5):313-319, 2021. e-Pub 2021. PMID: 33723371.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V, COVID19 and Cancer Clinical Trials Working Group. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 18(5):320, 2021. e-Pub 2021. PMID: 33758378.
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
Patnaik MM, Mughal TI, Brooks C, Lindsay R, Pemmaraju N. Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. Leuk Lymphoma:1-19. e-Pub 2021. PMID: 33999767.
Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
Wang W, Khoury JD, Miranda RN, Jorgensen JL, Xu J, Loghavi S, Li S, Pemmaraju N, Nguyen T, Medeiros LJ, Wang SA. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica 106(4):1047-1055, 2021. e-Pub 2021. PMID: 32241840.
Borthakur G, Ofran Y, Tallman MS, Foran J, Uy GL, DiPersio JF, Showel MM, Shimoni A, Nagler A, Rowe JM, Altman JK, Abraham M, Peled A, Shaw S, Bohana-Kashtan O, Sorani E, Pereg Y, Foley-Comer A, Oberkovitz G, Lustig TM, Glicko-Kabir I, Aharon A, Vainstein-Haras A, Kadosh SE, Samara E, Al-Rawi AN, Pemmaraju N, Bueso-Ramos C, Cortes JE, Andreeff M. BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study. Cancer 127(8):1246-1259, 2021. e-Pub 2020. PMID: 33270904.
Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leuk Lymphoma 62(4):1-14, 2021. e-Pub 2020. PMID: 33283580.
Pemmaraju N, Chen NC, Verstovsek S. Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 35(2):409-429, 2021. e-Pub 2021. PMID: 33641877.
Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. e-Pub 2021. PMID: 33793970.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. PMID: 33792630.
Batta K, Bossenbroek HM, Pemmaraju N, Wilks DP, Chasty R, Dennis M, Milne P, Collin M, Beird HC, Taylor J, Patnaik MM, Cargo CA, Somervaille TCP, Wiseman DH. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia. e-Pub 2021. PMID: 33833384.
Pemmaraju N. A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic. Cancer. e-Pub 2021. PMID: 33891316.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. PMID: 33885753.
Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv 5(8):2156-2164, 2021. PMID: 33885751.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur G. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 35(3):691-700, 2021. e-Pub 2020. PMID: 32561839.
Chen NC, Borthakur G, Pemmaraju N. Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. Leuk Lymphoma 62(3):1-10, 2021. e-Pub 2020. PMID: 33161793.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2020. PMID: 33264443.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov 2(2):125-134, 2021. e-Pub 2020. PMID: 33681815.
Pemmaraju N. Targeting the p-D-C: easy as C-D-1-2-3?. Blood 137(10):1277-1278, 2021. PMID: 33704391.
Reville PK, Kantarjian HM, Ravandi F, Jabbour E, DiNardo CD, Daver N, Pemmaraju N, Ohanian M, Alvarado Y, Xiao L, Alatrash G, Loghavi S, Rausch CR, Borthakur G, Konopleva M, Cortes J, Kadia TM. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J 11(3):60, 2021. e-Pub 2021. PMID: 33731681.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2020. PMID: 33119202.
Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2020. PMID: 33156969.
Wilson NR, Fang H, Loghavi S, Wang W, Tang G, Haltom RO, Rausch CR, McClain KL, Rao KV, Popat UR, Fayad LE, Champa N, Calvo KR, Allen CE, Kadia TM, Pemmaraju N. Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation. Br J Haematol 192(3):667-671, 2021. e-Pub 2020. PMID: 33238033.
Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11(2):25, 2021. e-Pub 2021. PMID: 33563904.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 14(1):34, 2021. e-Pub 2021. PMID: 33618754.
Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E. Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):1-13, 2021. e-Pub 2020. PMID: 32392559.
Abou Dalle I, Kantarjian HM, Ravandi F, Daver N, Wang X, Jabbour E, Estrov Z, DiNardo CD, Pemmaraju N, Ferrajoli A, Jain N, Wang SA, Jammal N, Borthakur G, Naqvi K, Pelletier S, Pierce S, Andreeff M, Garcia-Manero G, Cortes JE, Kadia TM. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. e-Pub 2021. PMID: 33449377.
Jammal N, Rausch CR, Kadia TM, Pemmaraju N. Cell Cycle Inhibitors for the Treatment of Acute Myeloid Leukemia: A Review of Phase 2 & 3 Clinical Trials. Expert Opin Emerg Drugs:1-9. e-Pub 2020. PMID: 33161749.
Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NG. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol 13(1):132, 2020. e-Pub 2020. PMID: 33032648.
El Hussein S, Lyapichev KA, Crane GM, Mirza KM, Pemmaraju N, Medeiros LJ, Khoury JD, Loghavi S. Social Media for Hematopathologists: Medical Practice Reinvented-#Hemepath. Curr Hematol Malig Rep 15(5):383-390, 2020. e-Pub 2020. PMID: 33128122.
Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3). Am J Hematol. e-Pub 2020. PMID: 32886803.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. e-Pub 2020. PMID: 32896301.
Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F, Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working group. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. e-Pub 2020. PMID: 32894785.
Cherng HJ, Jain N, Thakral B, Muzzafar T, Miranda RN, Tan D, Rashid A, Kalhor N, Hahn AW, Byers LA, Parseghian CM, Ferrajoli A, Pemmaraju N. Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leuk Res 98:106445. e-Pub 2020. PMID: 32937250.
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma:1-8. e-Pub 2020. PMID: 32755333.
Aung PP, Pemmaraju N, Torres-Cabala CA, Duvic M, Konopleva M, Khoury JD, Prieto VG. Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall. J Dermatol. e-Pub 2020. PMID: 32770556.
Brown SA, Daly RP, Duma N, Yang EH, Pemmaraju N, Parwani P, Choi AD, Lopez-Mattei J. Leveraging Social Media for Cardio-Oncology. Curr Treat Options Oncol 21(10):83, 2020. e-Pub 2020. PMID: 32789716.
Pemmaraju N, Konopleva M. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv 4(16):4020-4027, 2020. PMID: 32841341.
Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. PMID: 32589978.
Pandey RK, DiPippo A, Kadia T, Pemmaraju N, Workeneh BT, Jabbour E, Ravandi F, Jain N. Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leuk Lymphoma:1-3. e-Pub 2020. PMID: 32654562.
Alotaibi AS, Abdulrazzaq M, Patel KP, Ravandi F, Konoplev S, Bueso-Ramos C, Yin CC, Muzzafar T, Tang G, Futreal A, Jain N, Konopleva MY, Pemmaraju N. Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant. Leuk Lymphoma:1-3. e-Pub 2020. PMID: 32657180.
Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes J. Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia. Am J Hematol. e-Pub 2020. PMID: 32681739.
Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol. e-Pub 2020. PMID: 32686139.
Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. e-Pub 2020. PMID: 32697338.
Hammond D, Pemmaraju N. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematol Oncol Clin North Am 34(3):565-574, 2020. e-Pub 2020. PMID: 32336420.
Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. e-Pub 2020. PMID: 32546726.
Mughal TI, Pemmaraju N, Psaila B, Radich J, Bose P, Lion T, Kiladjian JJ, Rampal R, Jain T, Verstovsek S, Yacoub A, Cortes JE, Mesa R, Saglio G, Van Etten RA. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematol Oncol. e-Pub 2020. PMID: 32592408.
Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48, 2020. e-Pub 2020. PMID: 32366841.
Navada SC, Garcia-Manero G, OdchimarReissig R, Pemmaraju N, Alvarado Y, Ohanian MN, John RB, Demakos EP, Zbyszewski PS, Maniar M, Woodman RC, Fruchtman SM, Silverman LR. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leuk Res 94:106369. e-Pub 2020. PMID: 32442785.
Lee SS, McCue D, Pemmaraju N. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Expert Rev Anticancer Ther. e-Pub 2020. PMID: 32460559.
Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Zeev E, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis. e-Pub 2020. PMID: 32236406.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. PMID: 32251497.
Garcia-Manero G, Pemmaraju N, Alvarado Y, Naqvi K, Ravandi F, Jabbour E, De Lumpa R, Kantarjian H, Advani A, Mukherjee S, Gerds A, Carraway HE, Nazha A, Iwamura H, Murase M, Bavisotto L, Kurman M, Maier G, Johansen M, Sekeres MA. Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leuk Lymphoma:1-11. e-Pub 2020. PMID: 32264726.
Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. PMID: 32330243.
Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel K, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver N. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. e-Pub 2020. PMID: 32356320.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. e-Pub 2020. PMID: 32099037.
Daver N, Price A, Benton CB, Patel K, Zhang W, Konopleva M, Pemmaraju N, Takahashi K, Andreeff M, Borthakur G. First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations. Front Oncol 10:1538, 2020. e-Pub 2020. PMID: 32984009.
Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver N. Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol 10:588876, 2020. e-Pub 2020. PMID: 33194747.
Beird HC, Khan M, Wang F, Alfayez M, Cai T, Zhao L, Khoury J, Futreal PA, Konopleva M, Pemmaraju N. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer J 9(12):99, 2019. e-Pub 2019. PMID: 31811114.
Alfayez M, Konopleva M, Pemmaraju N. Role of Tagraxofusp in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Expert Opin Biol Ther. e-Pub 2019. PMID: 31801379.
Economides MP, Rizzieri D, Pemmaraju N. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Curr Hematol Malig Rep 14(6):515-522, 2019. PMID: 31853773.
Alfayez M, Richard-Carpentier G, Jabbour E, Vishnu P, Naqvi K, Sasaki K, Cortes J, Pemmaraju N. Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. Br J Haematol 187(4):543-545, 2019. e-Pub 2019. PMID: 31584727.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134(Supplement_1):34, 2019. PMID: 31724006.
Ye MT, Wang Y, Wang SA, Pemmaraju N, Daver N, Verstovsek S, Zhang Y, Zuo Z, Medeiros LJ, You MJ. Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma:1-4. e-Pub 2019. PMID: 31750750.
Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. e-Pub 2019. PMID: 31553487.
Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma:1-5. e-Pub 2019. PMID: 31566032.
Economides MP, Verstovsek S, Pemmaraju N. Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. Curr Hematol Malig Rep. e-Pub 2019. PMID: 31372878.
Alfayez M, Burger JA, Kadia T, Xu TH, Szvalb AD, Pemmaraju N. Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma:1-2. e-Pub 2019. PMID: 31305193.
Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. e-Pub 2019. PMID: 31296578.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. e-Pub 2019. PMID: 31310323.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. e-Pub 2019. PMID: 31237017.
Sukswai N, Aung PP, Yin CC, Li S, Wang W, Wang SA, Ortega V, Lyapichev K, Nagarajan P, Alfattal R, Angelova E, Tang Z, Loghavi S, Kanagal-Shamanna R, Miranda RN, Pemmaraju N, Bhalla K, Konopleva M, Medeiros LJ, Khoury JD. Dual Expression of TCF4 and CD123 is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol. e-Pub 2019. PMID: 31261288.
Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, Yin CC, Konopleva M, Zheng X, Wang J, Tang Z, Medeiros LJ, Prieto VG, Pemmaraju N, Khoury JD. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 11(5), 2019. e-Pub 2019. PMID: 31109153.
Economides MP, McCue D, Borthakur G, Pemmaraju N. Topoisomerase II inhibitors in AML: past, present, and future. Expert Opin Pharmacother:1-8. e-Pub 2019. PMID: 31136213.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. PMID: 31141631.
Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. e-Pub 2019. PMID: 30985931.
Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol. e-Pub 2019. PMID: 31005650.
Tallis E, Loghavi S, Jorgensen JL, Wang S, Khoury JD, Bueso-Ramos CB, Jain N, Borthakur G, Pemmaraju N. Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leuk Lymphoma:1-3. e-Pub 2019. PMID: 31012358.
Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Emerging translational science discoveries, clonal approaches and treatment trends in chronic myeloproliferative neoplasms. Hematol Oncol. e-Pub 2019. PMID: 31013548.
Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med 380(17):1628-1637, 2019. PMID: 31018069.
Pemmaraju N. Treatment advances in blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol 17(4):207-209, 2019. PMID: 31188810.
Boddu P, Carter BZ, Verstovek S, Pemmaraju N. SMAC mimetics as potential cancer therapeutics in myeloid malignancies. Br J Haematol. e-Pub 2019. PMID: 30836448.
Kharfan-Dabaja MA, Pemmaraju N, Mohty M. Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies. Clin Hematol Int 1(1):2-9, 2019. e-Pub 2019. PMID: 34595405.
Swaminathan M, Borthakur G, Kadia TM, Ferrajoli A, Alvarado Y, Pemmaraju N, Bodden K, Yearby B, Konopleva M, Khoury J, Bueso-Ramos C, Garcia-Manero G, DiNardo CD. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma:1-7. e-Pub 2019. PMID: 30773968.
Pemmaraju N, Konopleva M, Lane AA. More on Blastic Plasmacytoid Dendritic-Cell Neoplasms. N Engl J Med 380(7):695-6, 2019. e-Pub 2019. PMID: 30785714.
Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. e-Pub 2019. PMID: 30796023.
Benton CB, Boddu PC, DiNardo CD, Bose P, Wang F, Assi R, Pemmaraju N, Kc D, Pierce S, Patel K, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Cortes J, Kantarjian HM, Andreeff M, Verstovsek S. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer. e-Pub 2019. PMID: 30811597.
Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma:1-8. e-Pub 2019. PMID: 30632841.
Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol 12(1):1, 2019. e-Pub 2019. PMID: 30606227.
Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
Yilmaz M, Wang F, Loghavi S, Bueso-Ramos C, Gumbs C, Little L, Song X, Zhang J, Kadia T, Borthakur G, Jabbour E, Pemmaraju N, Short N, Garcia-Manero G, Estrov Z, Kantarjian H, Futreal A, Takahashi K, Ravandi F. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?. Blood Cancer J 9(2):7, 2019. e-Pub 2019. PMID: 30651532.
Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol 6(1):e29-e37, 2019. e-Pub 2018. PMID: 30545576.
Alfayez M, Ivan D, Pemmaraju N, Daver N, DiNardo CD. Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 30957058.
Economides MP, Konopleva M, Pemmaraju N. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm. Ther Adv Hematol 10:2040620719874733, 2019. e-Pub 2019. PMID: 31579499.
Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. PMID: 30501869.
Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA. Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. Curr Hematol Malig Rep 13(6):581-587, 2018. PMID: 30338458.
Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97(11):2071-2080, 2018. e-Pub 2018. PMID: 29951914.
Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol. e-Pub 2018. PMID: 30467242.
Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia TM, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov. e-Pub 2018. PMID: 30409776.
Guru Murthy GS, Pemmaraju N, Atallah E. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res 73:21-23, 2018. e-Pub 2018. PMID: 30189324.
Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. e-Pub 2018. PMID: 30181172.
Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis. Blood. e-Pub 2018. PMID: 30185431.
Abaza Y, Cortes J, Ravandi F, Kadia T, Garcia-Manero G, Pemmaraju N, Shetty A, Pierce S, Qiao W, Kantarjian HM, Borthakur G. Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol. e-Pub 2018. PMID: 30074261.
Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, Hu S, Zuo Z, Medeiros LJ, Kantarjian HM, Khoury JD. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv 2(15):1807-1816, 2018. PMID: 30054307.
Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM. Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. e-Pub 2018. PMID: 29723397.
Assi R, Kantarjian HM, Kadia TM, Pemmaraju N, Jabbour E, Jain N, Daver N, Estrov Z, Uehara T, Owa T, Cortes JE, Borthakur G. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. e-Pub 2018. PMID: 29660836.
Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol:JCO2017776757. e-Pub 2018. PMID: 29702001.
Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol. e-Pub 2018. PMID: 29550383.
Khan M, Muzzafar T, Kantarjian H, Badar I, Short N, Wang X, Chamoun K, Jain P, DiNardo C, Pemmaraju N, Bose P, Borthakur G, Cortes J, Verstovsek S, Garcia-Manero G, Estrov Z. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol. e-Pub 2018. PMID: 29557496.
Boddu PC, Wang SA, Pemmaraju N, Tang Z, Hu S, Li S, Xu J, Medeiros LJ, Tang G. 8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. Leuk Res 66:73-78. e-Pub 2018. PMID: 29407586.
Montalban-Bravo G, Takahashi K, Patel K, Wang F, Xingzhi S, Nogueras GM, Huang X, Pierola AA, Jabbour E, Colla S, Gañan-Gomez I, Borthakur G, Daver N, Estrov Z, Kadia T, Pemmaraju N, Ravandi F, Bueso-Ramos C, Chamseddine A, Konopleva M, Zhang J, Kantarjian H, Futreal A, Garcia-Manero G. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget 9(11):9714-9727, 2018. e-Pub 2018. PMID: 29515765.
Rausch CR, Paul S, Marx KR, Jabbour E, Pemmaraju N, Ferrajoli A, Kantarjian H. L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia. Clin Lymphoma Myeloma Leuk. e-Pub 2018. PMID: 29550108.
Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. e-Pub 2018. PMID: 29352703.
Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol 140(1):30-39, 2018. e-Pub 2018. PMID: 30071517.
Chamoun K, Loghavi S, Pemmaraju N, Konopleva M, Kroll M, Nguyen-Cao M, Hornbaker M, DiNardo CD, Kadia T, Jorgensen J, Andreeff M, Hu S, Benton CB. Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol 7:26, 2018. e-Pub 2018. PMID: 30323983.
Goethe E, Carter BZ, Rao G, Pemmaraju N. Glioblastoma and acute myeloid leukemia: malignancies with striking similarities. J Neurooncol. e-Pub 2017. PMID: 29196926.
Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. e-Pub 2017. PMID: 29226426.
DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M. Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies. Am J Hematol. e-Pub 2017. PMID: 29218851.
Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSM. Curr Hematol Malig Rep 12(6):598-604, 2017. PMID: 29105027.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X, Nogueras-Gonzalez G, Jabbour E, Bose P, Kadia T, Dinardo CD, Patel K, Bueso-Ramos C, Zhou L, Pierce S, Gergis R, Tuttle C, Borthakur G, Estrov Z, Luthra R, Hidalgo-Lopez J, Verstovsek S, Daver N. A Phase II Trial of Ruxolitinib in Combination with Azacytidine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms. Am J Hematol. e-Pub 2017. PMID: 29134664.
Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol. e-Pub 2017. PMID: 29143068.
Pemmaraju N, Utengen A, Gupta V, Thompson MA, Lane AA. Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. Curr Hematol Malig Rep. e-Pub 2017. PMID: 29064025.
Pemmaraju N. Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond. Curr Hematol Malig Rep. e-Pub 2017. PMID: 29064022.
Abaza Y, Kantarjian HM, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, Khoury JD, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Am J Hematol. e-Pub 2017. PMID: 29047158.
Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. e-Pub 2017. PMID: 29027261.
Pemmaraju N. Editorial overview: Emerging importance of social media for real-time communication in the modern medical era. Semin Hematol 54(4):175-176, 2017. e-Pub 2017. PMID: 29153076.
Pemmaraju N, Mesa RA, Majhail NS, Thompson MA. The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette. Semin Hematol 54(4):184-188, 2017. e-Pub 2017. PMID: 29153078.
Pemmaraju N, Thompson MA, Qazilbash M. Disease-specific hashtags and the creation of Twitter medical communities in hematology and oncology. Semin Hematol 54(4):189-192, 2017. e-Pub 2017. PMID: 29153079.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. e-Pub 2017. PMID: 28919634.
Tsai HJ, Jiang SS, Hung WC, Borthakur G, Lin SF, Pemmaraju N, Jabbour E, Bomalaski JS, Chen YP, Hsiao HH, Wang MC, Kuo CY, Chang H, Yeh SP, Cortes J, Chen LT, Chen TY. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Sci Rep 7(1):11253, 2017. e-Pub 2017. PMID: 28900115.
Pemmaraju N, Rytting ME. Questions on asparaginase-associated pancreatitis. Lancet Oncol 18(9):1148-1149, 2017. PMID: 28884687.
Boddu P, Benton CB, Wang W, Borthakur G, Khoury JD, Pemmaraju N. Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev. e-Pub 2017. PMID: 28965757.
Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. Blood. e-Pub 2017. PMID: 28774880.
Boddu P, Schlette E, Thakral B, Tang G, Pemmaraju N, Kadia T, Ferrajoli A, Ravandi F, Wierda W, Jain N. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther. e-Pub 2017. PMID: 28830803.
Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Concurrent diagnosis of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica. e-Pub 2017. PMID: 28860345.
Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T. Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience. Am J Hematol. e-Pub 2017. PMID: 28850699.
Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Jabbour E, Borthakur G, Daver N, Pemmaraju N, Pierce S, Cortes J, Kadia TM. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma:1-4. e-Pub 2017. PMID: 28838278.
Daher M, Hidalgo Lopez JE, Randhawa JK, Jabbar KJ, Wei Y, Pemmaraju N, Borthakur G, Kadia T, Konopleva M, Kantarjian HM, Hearn K, Estrov Z, Reyes S, Bueso-Ramos CE, Garcia-Manero G. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol 92(7):674-682, 2017. e-Pub 2017. PMID: 28370157.
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. e-Pub 2017. PMID: 28708931.
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma:1-8. e-Pub 2017. PMID: 28718728.
Daver N, Kantarjian H, Garcia-Manero G, Jabbour E, Borthakur G, Brandt M, Pierce S, Vaughan K, Ning J, Nogueras González GM, Patel K, Jorgensen J, Pemmaraju N, Kadia T, Konopleva M, Andreeff M, DiNardo C, Cortes J, Ward R, Craig A, Ravandi F. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica. e-Pub 2017. PMID: 28729302.
Boddu P, Takahashi K, Pemmaraju N, Daver N, Benton CB, Pierce S, Konopleva M, Ravandi F, Cortes J, Kantarjian H, DiNardo CD. Influence of IDH on FLT3ITD status in newly diagnosed AML. Leukemia. e-Pub 2017. PMID: 28751773.
Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(7):1659, 2017. e-Pub 2017. PMID: 28338082.
Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116. e-Pub 2017. PMID: 28601551.
Ragon BK, Daver N, Garcia-Manero G, Ravandi F, Cortes J, Kadia T, Oran B, Ohanian M, Ferrajoli A, Pemmaraju N, Kantarjian HM, Borthakur G. Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia. Am J Hematol. e-Pub 2017. PMID: 28494506.
Pemmaraju N, Thompson MA, Mesa RA, Desai T. Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends. J Oncol Pract:JOP2017021634. e-Pub 2017. PMID: 28514195.
Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. e-Pub 2017. PMID: 28387922.
Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res 57:85-88. e-Pub 2017. PMID: 28324773.
Alfonso A, Montalban-Bravo G, Takahashi K, Jabbour EJ, Kadia T, Ravandi F, Cortes J, Estrov Z, Borthakur G, Pemmaraju N, Konopleva M, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. Am J Hematol. e-Pub 2017. PMID: 28370097.
Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, O'Brien S, Wang X, Huang X, Wang SA, Konopleva M, Konoplev S, Kadia T, Garris R, Pierce S, Garcia-Manero G, Cortes J, Ravandi F. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. e-Pub 2017. PMID: 28052371.
Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Novel BET protein proteolysis targeting chimera (BET-PROTAC) exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Leukemia. e-Pub 2017. PMID: 28042144.
Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, Hogdal LJ, Galinsky I, Morgan EA, Aster JC, Davids MS, LeBoeuf NR, Stone RM, Konopleva M, Pemmaraju N, Letai A, Lane AA. Blastic Plasmacytoid Dendritic Cell Neoplasm is Dependent on BCL-2 and Sensitive to Venetoclax. Cancer Discov. e-Pub 2016. PMID: 27986708.
Pinnix CC, Chi L, Jabbour EJ, Milgrom SA, Smith GL, Daver N, Garg N, Cykowski MD, Fuller G, Cachia D, Kamiya C, Woodman K, Dinardo C, Jain N, Kadia TM, Pemmaraju N, Ohanian M, Konopleva M, Kantarjian HM, Dabaja BS. Dorsal Column Myelopathy after Intrathecal Chemotherapy for Leukemia. Am J Hematol. e-Pub 2016. PMID: 27874212.
Ohanian M, Pemmaraju N, Rozovski U, Alattar ML, Estrov Z, Kundra V, Tung C, Ravandi F, Manning J, Abruzzo LV. Ocular extramedullary myeloid leukaemia. Br J Haematol. e-Pub 2016. PMID: 27879987.
Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. e-Pub 2016. PMID: 27741352.
Montalban-Bravo G, Huang X, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. e-Pub 2016. PMID: 27795561.
Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. Am J Hematol. e-Pub 2016. PMID: 27673440.
Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda W. PET-positive lymphadenopathy in CLL - Not always Richter transformation. Am J Hematol. e-Pub 2016. PMID: 27677095.
Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. e-Pub 2016. PMID: 27677740.
Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. e-Pub 2016. PMID: 27479888.
Pemmaraju N, Gupta V, Thompson MA, Lane AA. Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Curr Hematol Malig Rep. e-Pub 2016. PMID: 27492117.
Pemmaraju N, Utengen A, Gupta V, Kiladjian JJ, Mesa R, Thompson MA. Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM. Curr Hematol Malig Rep. e-Pub 2016. PMID: 27492118.
Naqvi K, Daver N, Pemmaraju N, Bose P, Garcia-Manero G, Cortes J, Kantarjian HM, Verstovsek S. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma:1-6. e-Pub 2016. PMID: 27494751.
Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. e-Pub 2016. PMID: 27509035.
Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep 4(8):765-7, 2016. e-Pub 2016. PMID: 27525080.
Vitale C, Jabbour E, Lu X, Yabe M, Shamanna RK, Daver N, Pemmaraju N, Bueso-Ramos CE, Takahashi K. Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. Am J Hematol 91(4):E274-6, 2016. e-Pub 2016. PMID: 26798971.
Jain P, Nagarajan P, Prayag P, Benton CB, Kadia T, Groisberg R, Kontoyiannis DP, Mulanovich VE, Pemmaraju N. Mixed angioinvasive Exserohilum and Scedosporium infection in a patient with AML. Am J Hematol. e-Pub 2016. PMID: 27341684.
Galloway-Peña JR, Smith DP, Sahasrabhojane P, Ajami NJ, Wadsworth WD, Daver NG, Chemaly RF, Marsh L, Ghantoji SS, Pemmaraju N, Garcia-Manero G, Rezvani K, Alousi AM, Wargo JA, Shpall EJ, Futreal PA, Guindani M, Petrosino JF, Kontoyiannis DP, Shelburne SA. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer. e-Pub 2016. PMID: 27142181.
Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented berlin-frankfurt-münster (ABFM), in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL), and comparison to the hyper-CVAD regimen. Am J Hematol. e-Pub 2016. PMID: 27178680.
Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O'Brien S, Wierda W, Garcia-Manero G, Thomas D, Pierce S, Verstovsek S, Borthakur G, Cortes J. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk 16(4):213-222.e2, 2016. e-Pub 2016. PMID: 26838606.
Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol 14(4):220-222, 2016. PMID: 27166602.
Jain P, Tang G, Konoplev SN, Kanagal-Shamanna R, Wang SA, Pemmaraju N, Daver N, Estrov Z. Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B cell acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations. Am J Hematol 91(3):354-5, 2016. e-Pub 2016. PMID: 26437693.
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Shamanna RK, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 127(10):1269-75, 2016. e-Pub 2016. PMID: 26729897.
Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk 16(3):152-62, 2016. e-Pub 2015. PMID: 26796981.
Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia 30(2):268-73, 2016. e-Pub 2015. PMID: 26365212.
Perales MA, Drake EK, Pemmaraju N, Wood WA. Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer. Curr Hematol Malig Rep. e-Pub 2016. PMID: 26893061.
Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant 22(1):47-53, 2016. e-Pub 2015. PMID: 26343946.
Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer 122(2):238-48, 2016. e-Pub 2015. PMID: 26479889.
Jain P, Tang G, Huh YO, Yin CC, Zuo Z, Pemmaraju N, Estrov Z, Daver N. Philadelphia - positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation. Am J Hematol. e-Pub 2016. PMID: 26799924.
Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social Media and Myeloproliferative Neoplasms (MPN)-Focus on Twitter and the Development of a Disease-specific Community: #MPNSM. Curr Hematol Malig Rep 10(4):413-20, 2015. e-Pub 2015. PMID: 26411990.
Pemmaraju N. The Sacred Trust. Am J Kidney Dis 66(6):A17-9, 2015. PMID: 26593318.
Pemmaraju N, Mesa R. Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs). Hematology Am Soc Hematol Educ Program 2015(1):649-51, 2015. PMID: 26637784.
Jain P, Verstovsek S, Wang W, Loghavi S, Torres HA, Estrov Z, Patel KP, Pemmaraju N. DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leuk Lymphoma:1-5. e-Pub 2015. PMID: 26700872.
Jain P, Kantarjian H, Jabbour E, Gonzalez GN, Borthakur G, Pemmaraju N, Daver N, Gachimova E, Ferrajoli A, Kornblau S, Ravandi F, O'Brien S, Cortes J. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2(9):e376-e383, 2015. PMID: 26436130.
Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. e-Pub 2015. PMID: 26432046.
Kadia T, Kantarjian H, Garcia-Manero G, Borthakur G, Wang X, Patel K, Jabbour E, Brandt M, Daver N, Pemmaraju N, Pierce S, Cortes J, Ravandi F. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol 170(4):590-3, 2015. e-Pub 2015. PMID: 25716073.
Benton CB, Nazha A, Pemmaraju N, Garcia-Manero G. Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol 95(2):222-42, 2015. e-Pub 2015. PMID: 25869097.
Jain P, Hu S, Jabbour E, Takahashi K, Pemmaraju N, O'Brien S, Mulanovich VE, Estrov Z. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia. Am J Hematol 90(8):752-3, 2015. e-Pub 2015. PMID: 25850565.
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica 100(7):927-34, 2015. e-Pub 2015. PMID: 25682597.
Gowin K, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Kosiorek H, Dueck A, Mesa R. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. Leuk Res 39(7):684-8, 2015. e-Pub 2015. PMID: 25922307.
*Kazmi SM, *Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(6):358-63, 2015. e-Pub 2014. PMID: 25630528.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. e-Pub 2015. PMID: 26183878.
Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis. Haematologica. e-Pub 2015. PMID: 26088933.
*Loghavi S, *Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125(21):3360-3363, 2015. PMID: 25999449.
Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186-93, 2015. e-Pub 2015. PMID: 26688093.
Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O'Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol 168(5):646-53, 2015. e-Pub 2014. PMID: 25312977.
Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S. A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(3):171-6, 2015. e-Pub 2014. PMID: 25441108.
Pemmaraju N, Chang E. Healing words. CMAJ. e-Pub 2015. PMID: 25733740.
Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju N. Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis -TAFRO syndrome. Am J Hematol. e-Pub 2015. PMID: 25808231.
Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(2):110-4, 2015. e-Pub 2014. PMID: 25107338.
Kadia TM, Kantarjian HM, Thomas DA, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Pemmaraju N, Daver N, Wang X, Jain P, Pierce S, Brandt M, Garcia-Manero G, Cortes J, Borthakur G. Phase II Study of Methotrexate, Vincristine, Pegylated-Asparaginase, and Dexamethasone (MOpAD) in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Am J Hematol 90(2):120-4, 2015. e-Pub 2014. PMID: 25368968.
DiNardo CD, Tang G, Pemmaraju N, Wang SA, Pike A, Garcia-Manero G, Cortes J, Bueso-Ramos C, Kantarjian HM. Acute Myeloid Leukemia With t(10;11): A Pathological Entity With Distinct Clinical Presentation. Clin Lymphoma Myeloma Leuk 15(1):47-51, 2015. e-Pub 2014. PMID: 25081372.
Pemmaraju N, Kantarjian H, Garcia-Manero G, Pierce S, Cardenas-Turanzas M, Cortes J, Ravandi F. Improving Outcomes for Patients with Acute Myeloid Leukemia in First Relapse: A Single Center Experience. Am J Hematol 90(1):27-30, 2015. e-Pub 2014. PMID: 25251041.
Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo C, Hirsch-Ginsberg C, Wang SA, Medeiros LJ, Chin L, Patel KP, Ravandi F, Futreal A, Bueso-Ramos CE. Identification of a Novel Fusion Gene, IRF2BP2-RARA, in Acute Promyelocytic Leukemia. J Natl Compr Canc Netw 13(1):19-22, 2015. PMID: 25583766.
Pemmaraju N, Sasaki K, Johnson D, Daver N, Afshar-Kharghan V, Chen M, Ahmed S, Colen RR, Kwon M, Huh Y, Borthakur G. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. Front Oncol 5:29, 2015. e-Pub 2015. PMID: 25717439.
Pemmaraju N, Moliterno AR. From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. Am Soc Clin Oncol Educ Book 35:139-45, 2015. PMID: 25993152.
Shelburne SA, Ajami NJ, Chibucos MC, Beird HC, Tarrand J, Galloway-Peña J, Albert N, Chemaly RF, Ghantoji SS, Marsh L, Pemmaraju N, Andreeff M, Shpall EJ, Wargo JA, Rezvani K, Alousi A, Bruno VM, Futreal PA, Petrosino JF, Kontoyiannis DP. Implementation of a Pan-Genomic Approach to Investigate Holobiont-Infecting Microbe Interaction: A Case Report of a Leukemic Patient with Invasive Mucormycosis. PLoS One 10(11):e0139851, 2015. e-Pub 2015. PMID: 26556047.
DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol 2(1):e12-20, 2015. e-Pub 2014. PMID: 26687423.
Pemmaraju N, Gill J, Krause JR. Hairy cell leukemia presenting with a lytic bone lesion. Proc (Bayl Univ Med Cent) 28(1):65-6, 2015. PMID: 25552803.
Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer 120(23):3660-8, 2014. e-Pub 2014. PMID: 25042398.
Pemmaraju N, Shetty AV, Prieto VG, Jain N, Kontoyiannis DP, Borthakur G. Disseminated Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus) in a patient with acute myeloid leukemia. Eur J Haematol 93(6):543-4, 2014. e-Pub 2014. PMID: 24592915.
Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res 38(10):1212-6, 2014. e-Pub 2014. PMID: 25217891.
Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38(9):1126-9, 2014. e-Pub 2014. PMID: 25047979.
DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi F. Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents. Leuk Lymphoma 55(8):1925-9, 2014. e-Pub 2014. PMID: 24138309.
Geethakumari PR, Hoffmann MS, Pemmaraju N, Hu S, Jorgensen JL, O'Brien S, Daver N. Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge. Clin Lymphoma Myeloma Leuk 14(4):e115-8, 2014. e-Pub 2014. PMID: 24589157.
Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs 23(7):943-54, 2014. e-Pub 2014. PMID: 24749672.
Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to the interleukin-3 receptor, in patients with blastic plasmacytoid dendritic cell neoplasm. Blood 124(3):385-92, 2014. e-Pub 2014. PMID: 24859366.
Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi F. Mutated Nucleophosmin-1 (NPM1) in patients with Acute Myeloid Leukemia (AML) in remission and relapse. Leuk Lymphoma 55(6):1337-44, 2014. e-Pub 2013. PMID: 24004182.
Jain P, Pemmaraju N, Ravandi F. Update on the Biology and Treatment Options for Hairy Cell Leukemia. Curr Treat Options Oncol 15(2):187-209, 2014. e-Pub 2014. PMID: 24652320.
Jain P, Baez-Vallecillo L, Huh YO, Benjamini O, Abruzzo L, O'Brien S, Pemmaraju N, Keating M, Gagel RF, Estrov Z. Atypical chronic lymphocytic leukemia (CLL) with polyglandular autoimmune endocrinopathy (PGA) type II - a complex profile. Leuk Lymphoma 55(4):944-6, 2014. e-Pub 2014. PMID: 23829280.
Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of Hyper-CVAD plus nelarabine as frontline therapy in adult T cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (LL)-MD Anderson cancer center experience. Leukemia 28(4):973-5, 2014. e-Pub 2013. PMID: 24157581.
Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G. Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics. Clin Lymphoma Myeloma Leuk 14(2):163-71, 2014. e-Pub 2014. PMID: 24461514.
DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958-61, 2014. e-Pub 2014. PMID: 24492324.
Pemmaraju N, Gill J, Gupta S, Krause JR. Triple-hit lymphoma. Proc (Bayl Univ Med Cent) 27(2):125-7, 2014. PMID: 24688198.
Pemmaraju N, Chang E, Daver N, Patel K, Jorgensen J, Sabloff B, Verstovsek S, Borthakur G. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. Front Oncol 4:130, 2014. e-Pub 2014. PMID: 24918086.
Pemmaraju N, Cortes J. Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. Acta Haematol 132(3-4):298-306, 2014. e-Pub 2014. PMID: 25228555.
Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podoloff DA, Moon B, Daver N, Borthakur G. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. Front Oncol 4:297, 2014. e-Pub 2014. PMID: 25401088.
Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol 88(12):1055-61, 2013. e-Pub 2013. PMID: 23940084.
Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients 60 years with newly diagnosed acute myeloid leukemia (AML). Am J Hematol 88(11):961-6, 2013. e-Pub 2013. PMID: 23877926.
Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. Blood 122(19):3387-8, 2013. PMID: 24203930.
Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G. Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood 122(16):2807-11, 2013. e-Pub 2013. PMID: 23896412.
Jain P, Lin P, Bueso-Ramos C, Verstovsek S, Pemmaraju N. Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. Eur J Haematol 91(4):378-9, 2013. e-Pub 2013. PMID: 23772772.
Strati P, Daver N, Ravandi F, Pemmaraju NN, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J. Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13 Suppl 2:S276-81, 2013. e-Pub 2013. PMID: 23969309.
Ohanian M, Faderl S, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes J, Estrov Z. Is acute myeloid leukemia a liquid tumor?. Int J Cancer 133(3):534-43, 2013. e-Pub 2013. PMID: 23280377.
Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A. Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy. Clin Lymphoma Myeloma Leuk 13(4):435-40, 2013. e-Pub 2013. PMID: 23763915.
Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MH. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 13(4):485-92, 2013. e-Pub 2013. PMID: 23769669.
Takahashi K, Kantarjian H, Pemmaraju N, Andreeff M, Borthakur G, Faderl S, Garcia-Manero G, Pierce S, Luthra R, Cardenas-Turanzas M, Estrov Z, Ravandi F, Cortes J. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. Br J Haematol 161(5):659-66, 2013. e-Pub 2013. PMID: 23530930.
Ohanian M, Borthakur G, Quintas-Cardama A, Mathisen M, Cortés JE, Estrov Z, Pemmaraju N. Ocular Granulocytic Sarcoma: A Case Report and Literature Review of Ocular Extramedullary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(1):93-6, 2013. e-Pub 2012. PMID: 23017332.
Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029-35, 2012. e-Pub 2012. PMID: 22271898.
Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen related side effects. Ann Oncol 23(6):1471-4, 2012. e-Pub 2011. PMID: 22085764.
Pemmaraju N, Hamilton JP, Cameron AM, Sisson S, Moliterno AR. Abdominal venous thrombosis presenting in Myeloproliferative neoplasm with JAK2 V617F mutation: a case report. J Med Case Rep 6(1):102, 2012. e-Pub 2012. PMID: 22480324.
Pemmaraju N, Kantarjian H, Ravandi F, Cortes J. FLT3 inhibitors in the treatment of acute myeloid leukemia: The start of an era?. Cancer 117(15):3293-304, 2011. e-Pub 2011. PMID: 21319142.
Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, Spivak JL, Moliterno AR. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 95(7):1090-7, 2010. e-Pub 2010. PMID: 20133898.
Pemmaraju N, Feldman LS. Solifenacin-induced small bowel pseudo-obstruction. J Hosp Med 3(2):176-8, 2008. PMID: 18438799.
Pemmaraju N, Moliterno AR, Williams DM, Rogers O, Spivak JL. The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis. Leukemia 21(10):2210-2, 2007. e-Pub 2007. PMID: 17507997.
Pemmaraju N, Dassopoulos T, Moliterno AR. An absorbing problem. Am J Med 120(3):229-30, 2007. PMID: 17349442.

Abstracts

Naveen Pemmaraju, Nathaniel R Wilson, Guillermo Garcia-Manero, Koji Sasaki, Joseph D. Khoury, Nitin Jain, Gautam Borthakur, Farhad Ravandi, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Elias J. Jabbour, Sherry A. Pierce, John Villarreal, Muzaffar H. Qazilbash, Marina Konopleva, Hagop Kantarjian. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. Blood 138(Supp 1), 2021.
Naveen Pemmaraju, Giovanni Martinelli, Elisabetta Todisco, Andrew A. Lane, Evelyn Acuña-Cruz, Eric Deconinck, Eunice S. Wang, Kendra Sweet, David A Rizzieri, Giovanni Marconi, Luca Mazzarella, Daniel J. DeAngelo, Pau Montesinos, Federica Gigli, Harry P. Erba, Marina Konopleva, Hagop Kantarjian, Roland B. Walter, Ahmed Aribi, Delphine Lebon, Moshe Y. Levy, Callum M Sloss, Kara E Malcolm, Patrick A Zweidler-McKay, Naval Daver. Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 138(Supp 1), 2021.
Naveen Pemmaraju, Kapil N. Bhalla, Naval Daver, Nathaniel R Wilson, Warren C. Fiskus, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, Courtney D. DiNardo, Elias J. Jabbour, Jan A. Burger, Nicholas J. Short, Yesid Alvarado, Nitin Jain, Lucia Masarova, Srdan Verstovsek, Ghayas C. Issa, Wei Qiao, Joseph D. Khoury, Sherry A. Pierce, Darla Miller, Marina Konopleva, Hagop Kantarjian, Gautam Borthakur. Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 138(Supp 1), 2021.
Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice S. Wang, Andrew A. Lane, Haris Ali, Anthony S. Stein, Abdulraheem Yacoub, David A. Rizzieri, Sumithira Vasu, Vikas Gupta, Sangmin Lee, Gary J. Schiller, James M. Foran, Minakshi S. Taparia, Todd L. Rosenblat, Roland B. Walter, Debra Sieminski, Madhu Anant, Mrinal M. Patnaik, Tariq I. Mughal, Marina Konopleva. Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Blood 138(Supp 1), 2021.
Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, Anthony S. Stein, Sumithira Vasu, David A. Rizzieri, Eunice S. Wang, Hagop Kantarjian, Christopher L Brooks, Tariq I. Mughal, Andrew A. Lane. Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement. Blood 138(Supp 1), 2021.
Pemmaraju N. Results from Ongoing Ph 2 Registration Study of SL-401 in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). EHA 21st Congress, 2016.
Koji Sasaki, Hagop M. Kantarjian, Farhad Ravandi, Deborah A. Thomas, Jorge E. Cortes, Pemmaraju N, Tapan M. Kadia, Nicholas James Short, Ghayas C. Issa, Rebecca S. Garris, Vicky Jeanis, H. Gal Moore, Guillermo Garcia-Manero, Gautam Borthakur, William G. Wierda, Evguenia Gachimova, Susan Mary O'Brien, Elias Jabbour. Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-posititve (PH+) acute lymphoblastic leukemia (ALL). ASCO Annual Meeting 2016, 2016.
Boyu Hu, Hagop M. Kantarjian, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Alessandra Ferrajoli, William G. Wierda, Guillermo Garcia-Manero, Naval Guastad Daver, Pemmaraju N, Sara Dellasala, Sherry Pierce, Elias Jabbour, Jorge E. Cortes. Survival outcomes of sustained MR4.5 in patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKI). ASCO Annual Meeting 2016, 2016.
Pemmaraju N, Andrew A. Lane, Kendra Lynn Sweet, Anthony Selwyn Stein, Sumithira Vasu, William G. Blum, David Rizzieri, Eunice S. Wang, Madeleine Duvic, Janice Chen, Shay Shemesh, Peter McDonald, Christopher Brooks, Hagop M. Kantarjian, Marina Konopleva. Oral Presentation:Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing. ASCO Annual Meeting 2016, 2016.
Jorge E. Cortes, Hagop M. Kantarjian, Tapan M. Kadia, Gautam Borthakur, Marina Konopleva, Guillermo Garcia-Manero, Naval Guastad Daver, Pemmaraju N, Elias Jabbour, Zeev Estrov, Abhijit Ramachandran, Jamil Paradela, Blake Pond, Farhad Ravandi, Madhuri Vusirikala, Prapti Arvind Patel, Mark J. Levis, Alexander E. Perl, Michael Andreeff, Robert Collins. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. ASCO Annual Meeting 2016, 2016.
Sasaki K, O'Brien S, Ravandi F, Thomas D, Moore HG, Cortes J, Pemmaraju N, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, Jeanis V, Borthakur G, Wierda WG, Ferrajoli A, Kantarjian H, Jabbour E. Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL). Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015.
Sasaki K, O’Brien S, Thomas DA, Khouri M, Yilmaz M, Garcia-Manero G, Ravandi F, Borthakur G, Garris R, Gachimova E, DiNardo C, Pemmaraju N, Cortes J, Kantarjian H, Jabbour E. Phase II study of hyper-CMAD with liposomal vincristine as frontline therapy for patients with acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015.
Abraham M, Al-Rawi A, Pereg Y, Klein S, Wald H, Eizenberg O, Bulvik B, Russovsky L, Vainstein A, Arnon Aharon, McQueen T, Pemmaraju N, Cortes J, Amnon Peled, Borthakur G, Andreeff M. BL-8040, A NOVEL CXCR4 INHIBITOR, AFFECTS AML BLASTS SURVIVAL AND INDUCES THEIR TERMINAL DIFFERENTIATION. Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015.
Yilmaz M, Koji Sasaki, Ravandi F, Cortes J, Garcia-Manero G, Kadia T, Daver N, Pemmaraju N, Borthakur G, DiNardo C, Takahashi K, O’Brien S, Estrov Z, Pike A, Brandt M, Kantarjian H. Randomized Phase II Study of Clofarabine or Fludarabine Combined with Idarubicin and Cytarabine for the Treatment of Newly Diagnosed AML. Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015.
Vitale C, Ciccone M, Hinojosa C, Keating MJ, Pemmaraju N, O’Brien S, Wierda WG, Thomas DA, Borthakur G, Ohanian M, Burger JA, Ferrajoli A. Front-line Treatment with Ofatumumab in Elderly Unfit Patients with CLL. Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015.
Daver N, Cortes J, Zhou L, Pierce S, Pemmaraju N, Jabbour E, Borthakur G, Estrov Z, Wynn F, Van Derbur S, Garcia-Manero G, Kantarjian H, Verstovsek S. Combination Approach with Ruxolitinib and Azacytidine in Myelofibrosis. Clinical Lymphoma, Myeloma & Leukemia 15(Supp 2), 2015.
Patel K; Routbort M; Noguera-Gonzalez G; Kantarjian HM, Jabbour E; Borthakur G; DiNardo C; Estrov Z, Daver N; Wierda W; Jain N; O’Brien S; Konopleva M; Cortes J; Pemmaraju N; Alvarado Y; Bueso-Ramos C; Luthra R; Singh R; Pierce S; Medeiros LJ; Bohannan Z; Huang X; Garcia-Manero G. Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. Blood 124(21), 2014.
Thomas DA; O'Brien S; Rytting M; Ravandi F; Jabbour E; Ferrajoli A; Estrov Z; Garcia-Manero G; Burger JA; Wierda W; Konopleva M; Andreeff M; Kornblau SM; Verstovsek S; Borthakur G; Kadia T; Garris R; Pemmaraju N; Daver N; Jain N; Jorge Cortes J; and Kantarjian HM. Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). Blood 124(21), 2014.
Garcia-Manero G; Huang X; Cabrero M; DiNardo CD; Pemmaraju N; Daver NG; Borthakur G; Wierda WG; Kadia T; Alvarado Y; Cortes J; Jain N; Ravandi F; Jabbour E; Brandt M; Sneed T; Sukholutsky V; Pierce S; Bohannan Z; Kantarjian HM. A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. Blood 124(21), 2014.
Borthakur G; Nagler A; Ofran Y; Rowe JM; Altman JK; Frankfurt O; Tallman; Avivi I; Peled A; Pereg Y; Foley-Comer A; Russovsky L; Aharon A; McQueen T; Pemmaraju N; Bueso-Ramos CE; Cortes J; Andreeff M. BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. Blood 124(21), 2014.
Jabbour E; Sasaki K; Sekeres MA; Komrokji RS; Steensma DP, DeZern AE; Gail RJ; Daver NG; Pemmaraju N; Kadia T; DiNardo CD; Wang X; Nogueras-Gonzalez G; Borthakur G; Estrov Z; Kantarjian HM; Garcia-Manero G. Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. Blood 124(21), 2014.
Pinnamaneni P; Jorgensen J; Kantarjian HM; Jabbour E; Pierce SR; Brandt M; Wang SA; Konoplev S; Konopleva M; Kornblau SM; Kadia T; DiNardo CD; Pemmaraju N; Andreeff M; Estrov Z; Garcia-Manero G; Cortes JE; Ravandi F. Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia. Blood 124(21), 2014.
Kadia T; Borthakur G; Ferrajoli A; Daver NG; Jabbour E; Pemmaraju N; Verstovsek S; Burger JA; Wierda WG; Konopleva M; DiNardo CD; Jain N; Brandt M; Tuttle C; Wang X; Ravandi F; Garcia-Manero G; Cortes JE; Kantarjian HM. Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood 124(21), 2014.
Cabrero M; Garcia-Manero G; Sasaki K; Daver NG; Borthakur G; DiNardo CD; Cortes JE; Bohannan Z; Sukholutsky V; Ravandi F; Pierce S; Kadia TM; Pemmaraju N; Oran B; Champlin RE; Kantarjian HM; Jabbour E. Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood 124(21), 2014.
Jabbour E; Sasaki K; Daver N; Pemmaraju N; Jain N; Kadia TM; DiNardo CD; Borthakur G; Konopleva M; Faderl SH; O’Brien S; Cortes JE; Kantarjian HM; Garcia-Manero G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. Blood 124(21), 2014.
Daver N; Kantarjian HM; Garcia-Manero G; Pemmaraju N; Kadia TM; DiNardo CD; Jain N; Borthakur G; Jabbour E; Konopleva M; Cortes J; Craig AR; Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood 124(21), 2014.
Pemmaraju N; Kantarjian HM; O’Brien S; Borthakur G; Ravandi F; Verstovsek S; Daver NG; Garcia-Manero G; DiNardo CD; Skinner J; Konopleva M; Pierce S; Jabbour E; Cortes JE. Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Blood 124(21), 2014.
Randhawa J; Kantarjian HM; Borthakur G; Thompson PA; Konopleva M; Daver N; Pemmaraju N; Jabbour E; Kadia TM; Estrov Z; Ramachandran A; Paradela J; Andreef M; Levis M; Ravandi F; Cortes JE. Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations. Blood 124(21), 2014.
Cabrero M; Jabbour E; Daver N; Borthakur G; DiNardo CD; Cortes JE; Bohannan Z; Sukholutsky V; Ravandi F; Pierce S; Kadia T; Pemmaraju N; Kantarjian HM; Garcia-Manero G. Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up. Blood 124(21), 2014.
Takahashi K; Kantarjian HM; Jain P; Jabbour E; Wierda W; Pemmaraju N; Ferrajoli A; Dellasala SE; Pierce SR; Verstovsek S; Ravandi F; O’Brien S; Cortes JE. Propensity Score Matched Comparison of Dasatinib and Nilotinib As a Frontline Therapy in Newly Diagnosed CML with Chronic Phase. Blood 124(21), 2014.
Jabbour E; Sasaki K; Daver N; Pemmaraju N; DiNardo CD; Kadia T; Miller D; Sukholutsky V; Huang X; Borthakur G; Estrov Z; Kantarjian HM; Garcia-Manero G. Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). Blood 124(21), 2014.
Sasaki K; Strom SS; O’Brien S; Jabbour E; Ravandi F; Konopleva M; Borthakur G; Pemmaraju N; Daver N; Pierce SR; Kantarjian HM; Cortes JE. Chronic Myeloid Leukemia in Chronic Phase: Survival in the Era of Tyrosine Kinase Inhibitors Is Similar to That of the General Population in All Age Groups. Blood 124(21), 2014.
Jabbour E; Kantarjian HM; Thomas D; Sasaki K; Ravandi F; Cortes JE; Pemmaraju N; Kadia T; Garris R; Garcia-Manero G; Borthakur G; Wierda WG; O’Brien S. Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood 124(21), 2014.
Daver N; Cortes JE, Jabbour E; Pemmaraju N; Jain N; Estrov Z; Kornblau SM; Burger JA; Kantarjian HM; Newberry KJ; Verstovsek S. Ruxolitinib and Lenalidomide As a Combination Therapy for Patients with Myelofibrosis. Blood 124(21), 2014.
Duque AD; Cabrero M; Ravandi F; Pemmaraju N; Borthakur G; Kantarjian HM; Cortes JE; Kadia TM; Daver NG; Jabbour E; Garcia-Manero G; Sasaki K. Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience. Blood 124(21), 2014.
Duque AD; Randhawa J; Kantarjian HM; Pemmaraju N; Jabbour E; Ferrajoli A; Wierda WG; Estrov Z; Konopleva M; Ravandi F; Alvarado Y; Gandhi V; Borthakur G; Cortes JE. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML. Blood 124(21), 2014.
Gowin KL; Dueck AC; Verstovsek S; Daver NG; Pemmaraju N; Valdez R; Mesa RA. The Clinical Phenotype of Patients with Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis Whom Only Manifest WHO Grade 1 Fibrosis. Blood 124(21), 2014.
DiNardo CD; Daver N; Jabbour E; Kadia T; Borthakur G; Konopleva M; Pemmaraju N; Yang H; Wei Y; Wierda WG; Bueso-Ramos CE; Patel KP; Cortes JE; Ravandi F; Kantarjian HM; Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 124(21), 2014.
Daver N; Kantarjian HM; O'Brien S; Jabbour E; Pierce SR; Lim M; Borthakur G; Pemmaraju N; Konopleva M; DiNardo CD; Ravandi F; Garcia-Manero G; Cortes JE. Frequency and Impact of Molecular Response’s with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood 124(21), 2014.
Randhawa JK; Jabbar KJ; Kadia T; Borthakur G; Pemmaraju N; Daver N; Kantarjian HM; Cortes JE; Hearn K; Bueso-Ramos CE; Garcia-Manero G. Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation. Blood 124(21), 2014.
DiNardo CD; Aung FM; Martinez F; Daver N; Kadia T; Jain N; Jabbour E; Pemmaraju N; Reddy VM; Garcia-Manero G; Cortes JE; Ravandi F; Kantarjian HM; Lichtiger B; Freireich EJ. A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Prevention of Infection in AML Patients Undergoing Induction Therapy. Blood 124(21), 2014.
Jain P; Kantarjian HM; Jabbour E; Borthakur G; Pemmaraju N; Daver N; Gachimova E; Ferrajoli A; Kornblau SM; Ravandi F; O'Brien S; Cortes JE. Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 124(21), 2014.
Sasaki K; Jabbour E; Pemmaraju N; Daver NG; Kadia TM; DiNardo CD; Pierce SR; Borthakur G; Kantarjian HM; Garcia-Manero G. Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). Blood 124(21), 2014.
Sasaki K; Jabbour E; Kantarjian HM; Cortes JE; Garcia-Manero G; Borthakur G; Pierce SR; Pemmaraju N; O'Brien S; Ravandi F. Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience. Blood 124(21), 2014.
Badar T; Kantarjian HM; Ravandi F; Jabbour E; Borthakur G; Cortes JE; Pemmaraju N; Pierce SR; Daver N; Verstovsek S. Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF). Blood 124(21), 2014.
Daver N; Kantarjian HM; Garcia-Manero G; Pemmaraju N; Kadia TM; DiNardo CD; Jain N; Borthakur G; Jabbour E; Konopleva M; Cortes JE; Craig AR; Ravandi F. Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood 124(21), 2014.
Priyanka P, Sinha A, Khoury J, Patel K, Routbort M, Singh R, Luthra R, Pemmaraju N, Takahashi K, Muzzafar T. Chronic myelomonocytic leukemia: Next-generation sequencing in 30 treatment-naive cases. Journal of Clinical Oncology 32(15), 2014.
Daver NG, Kantarjian H, Pierce S, Brandt M, Dinardo CD, Pemmaraju N, Vaughan K, Garcia-Manero G, Jabbour E, Borthakur G, Kadia TM, Cortes JE, Craig A, Ravandi F. Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Journal of Clinical Oncology 32(15), 2014.
Shetty A, Cortes JE, Ravandi F, Kadia TM, Garcia-Manero G, Pemmaraju N, Pierce S, Kantarjian HM, Borthakur G. Hyperdiploidy in AML: Outcomes of acute myelogenous leukemia (AML) patients (pts) with a hyperdiploid karyotype. Journal of Clinical Oncology 32(15), 2014.
Pemmaraju N, Thomas DA, Kantarjian HM, Cortes JE, Khoury J, Manning JT, Medeiros LJ, O'Brien SM, Daver NG, Pierce S, Garcia-Manero G, Jabbour E, Jain N, Qazilbash MH, Faderl S, Frankel AE, Konopleva M. Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes. Journal of Clinical Oncology 32(15), 2014.
O'Brien SM, Jabbour E, Thomas DA, Ravandi F, Cortes JE, Pemmaraju N, Kadia TM, Garris R, Jeanis V, Garcia-Manero G, Borthakur G, Wierda WG, Kantarjian HM. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 32(15), 2014.
Andreeff M, Borthakur G, Zeng Z, Kelly MA, Wang RY, McQueen TJ, Qiu Y, Mak D, Burger JA, Daver NG, Pemmaraju N, Kadia TM, Jabbour E, Pierce S, Ravandi F, Garcia-Manero G, O'Brien SM, Cortes JE, Kantarjian HM, Konopleva M. Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients. Journal of Clinical Oncology 32(15), 2014.
Sasaki K, Kantarjian HM, Jain P, Jabbour E, Pemmaraju N, Wierda WG, Ferrajoli A, Dellasala S, Pierce S, Verstovsek S, Ravandi F, O'Brien SM, Cortes JE. Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily. Journal of Clinical Onoclogy 32(15), 2014.
Kadia TM, Cortes JE, Borthakur G, Garcia-Manero G, Jabbour E, Ferrajoli A, Verstovsek S, Ravandi F, Pemmaraju N, Daver NG, Konopleva M, Wang X, Kantarjian HM. Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML. Journal of Clinical Oncology 32(15), 2014.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Daver NG, Srdan Verstovsek S. Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase. Journal of Clinical Oncology 32(15), 2014.
Daver N, Kantarjian HM, Garcia-Manero G, Pemmaraju N, Kadia T, DiNardo C, Jain N, Borthakur G, Cortes J, Adam C, Ravandi F. Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). AACR Annual Meeting 2014, 2014.
Daver N, Kantarjian H, DeBose L, Jabbour E, Borthakur G, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo C, Ravandi F, Cortes J, Andreeff M, Konopleva M. Buparlisib, A PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I/II Trial of Patients with Advanced Leukemias. EHA Conference, Milano Italy, 2014.
Kantarjian HM, Jabbour E, Yee K, Kropf P, O'Connell C, Stock W, Tibes R, Rizzieri D, Walsh K, Griffiths EA, Roboz GJ, Savona M, Ervin T, Podoltsev NA, Pemmaraju N, Daver N, Garcia-Manero G, Borthakur G, Wierda WG, Ravandi F, Cortes JE, Brandwein JM, Odenike O, Feldman EJ, Chung W, Naim S, Choy G, Taverna P, Hao Y, Dimitrov G, Azab M, Issa J-P. ASH Annual Meeting 2013. First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML) 122, 2013.
Pemmaraju N, Shah D, Kantarjian HM, Wagner V, Orlowski RZ, Garcia-Manero G, Ravandi F, Pierce S, Takahashi K, Daver NG, Nazha A, Verstovsek S, Jabbour EJ, de Lima MJ, Champlin RE, Cortes JE, Qazilbash MH. Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). ASH Annual Meeting 2013 122, 2013.
Frankel AE, Woo JH, Mauldin JP, Carraway HE, Frankfurt O, Forman SJ, Vasu S, Pemmaraju N, Konopleva M, Hogge DE, Garanache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Bergstein I, Rowinsky E. An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH Annual Meeting 2013 122, 2013.
Jabbour E, Kantarjian H, Thomas DA, Ravandi F, Cortes JE, Faderl SH, Pemmaraju N, Kadia TM, Garris R, Hillary P, Garcia-Manero G, Borthakur G, Wierda WG, O'Brien S. Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting 2013 122, 2013.
Daver NG, Naqvi K, Kadia TM, DiNardo CD, Ravandi F, Nazha A, Borthakur G, Pemmaraju N, Brandt M, O'Brien S, Garcia-Manero G, Pierce SR, Jabbour E, Cortes JE, Kantarjian HM. Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age. ASH Annual Meeting 2013 122, 2013.
Rytting ME, Thomas DA, O'Brien S, Schroeder K, Garris R, Cortes JE, Ravandi F, Pemmaraju N, Daver N, Faderl SH, Franklin ARK, Borthakur G, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-Muenster Based Therapy For Young Adults With Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting 2013 122, 2013.
Nazha A, Garcia-Manero G, Kantarjian HM, Ravandi F, Borthakur G, Kadia TM, Jabbour E, Pemmaraju N, Daver NG, DiNardo CD, Miller D, Faderl SH. Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy. ASH Annual Meeting 2013 122, 2013.
DiNardo CD, Daver NG, Jain N, Pemmaraju N, Bueso-Ramos CE, Yin C, Pierce SR, Jabbour E, Quintás-Cardama A, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach. ASH Annual Meeting 2013 122, 2013.
Cortes JE, Borthakur G, Pemmaraju N, Daver N, Quintas-Cardama A, Ravandi F, Gachimova E, Estrov Z, Jabbour E, O'Brien S, Kantarjian H. Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP). ASH Annual Meeting 2013 122, 2013.
Kadia TM, Daver N, Virani F, Jabbour E, Pierce S, Pemmaraju N, Quintas-Cardama A, Borthakur G, O'Brien S, Kantarjian HM, Cortes JE. Incidence, Clinical Characteristics, and Prognostic Significance Of Chromosome 3q Abnormalities In Patients With CML Blast Phase. ASH Annual Meeting 2013 122, 2013.
Sasaki K, Kantarjian HM, Jabbour E, Quintas-Cardama A, Pierce S, Borthakur G, Kadia TM, Pemmaraju N, Ferrajoli A, O'Brien S, Cortes JE. Clinical Safety and Efficacy Of Nilotinib Or Dasatinib In Patients (Pts) With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) With Pre-Existing Liver and/Or Renal Dysfunction. ASH Annual Meeting 2013 122, 2013.
Nazha A, Ravandi F, Kantarjian HM, Huang X, Choi S, Garcia-Manero G, Jabbour EJ, Borthakur G, Kadia TM, Konopleva M, Cortes JE, Ferrajoli A, Kornblau SM, Andreeff M, Estrov Z, Daver NG, Pemmaraju N, Du M, Brandt M, Faderl S. Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <=60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). ASH Annual Meeting 2012, 2012.
Daver N, Kantarjian HM, Garcia-Manero G, Estrov Z, Konopleva M, Burger JA, O'Brien S, Ferrajoli A, Verstovsek S, Kadia TM, Jabbour EJ, Faderl S, Diaz-Pines-Mateo M, Pemmaraju N, Pierce SA, Cortes JE, Borthakur G. Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. ASH Annual Meeting 2012, 2012.
Jain P, Kantarjian HM, Thomas DA, Ravandi F, Kadia TM, Burger JA, Borthakur G, Cortes JE, Daver N, Jabbour EJ, Koller CA, Konopleva M, Pemmaraju N, Kelly MA, Garris R, O'Brien S, Faderl S. Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL). ASH Annual Meeting 2012, 2012.
Jabbour EJ, Kantarjian HM, Cameron Y, Ravandi F, Cortes JE, Garcia-Manero G, Ghanem H, Kadia TM, Faderl, O'Brien, Mathisen MS, Brandt M, Pemmaraju N, Thomas DA, Bass J, Borthakur G. Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen. ASH Annual Meeting 2012, 2012.
Kazmi SM, Kantarjian HM, Tran KM, Cortes JE, Ravandi F, Borthakur G, Jabbour EJ, Faderl S, Garcia-Manero G, Kadia GM, Daver N, Pierce SA, Nazha A, Quintas-Cardama A, Pemmaraju N. Cytogenetic and Molecular Charterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia. ASH Annual Meeting 2012, 2012.
Jain P, Kantarjian HM, Faderl S, Patel KP, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia TM, Daver NG, Nazha A, Rajyalakshmi L, Pierce SA, Cortes JE, Ravandi F. Mutant NPM1 is a Reliable marker of Minimal Residual Leukemia in Patients wtih Acute Myeloid Leukemia. ASH Annual Meeting 2012, 2012.
Takahashi K, Jabbour EJ, Wang X, Ghanem H, Pemmaraju N, Ravandi F, Cortes JE, Faderl S, Kadia TM, Borthakur G, Wierda WG, Pierce SA, Estrov Z, Kantarjian HM, Garcia-Manero G. Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis. ASH Annual Meeting 2012, 2012.
Ghanem H, Garcia-Manero G, Faderl S, Takahashi K, Ravandi F, Cortes JE, O'Brien SM, Daver NG, Katragadda L, Pemmaraju N, Pierce SA, Quintas-Cardama A, Kadia TM, Kantarjian HM, Jabbour EJ. Outcomes of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure. ASH Annual Meeting 2012, 2012.
Mathisen MS, Kantarjian HM, Ravandi F, Pemmaraju N, Garcia-Manero G, Cortes JE, O'Brien S, Quintas-Cardama A, Ghanem H, Daver NG, Pierce SA, Lira C, Faderl S, Jabbour E. Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML). ASH Annual Meeting 2012, 2012.
Ravandi F, Patel KP, Luthra R, Pierce SA, Borthakur G, Jabbour EJ, Kadia TM, Pemmaraju, N, Daver N, Konopleva M, Faderl S, Garcia-Manero G, Cortes JE, Kantarjian HM. Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents. ASH Annual Meeting 2012, 2012.
Takahashi K, Pemmaraju N, Beran M, Quintas-Cardama A, Cortes JE, Ravandi F, Faderl S, Verstovsek S, Kadia TM, Borthakur G, Jabbour EJ, Daver N, Estrov Z, Pierce SA, Garcia-Manero G. Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). ASH Annual Meeting 2012, 2012.
Jabbour EJ, Daver NG, Dong T, Kadia TM, O'Brien S, Cortes JE, Ravandi F, Pemmaraju N, Ghanem H, Faderl S, Borthakur G, Kantarjian HM, Garcia-Manero G. Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) AFter Hypomethylating Agent (HMA). ASH Annual Meeting 2012, 2012.
Strati P, Kantarjian HM, Cortes JE, Ravandi F, Pemmaraju N, Garcia-Manero G, Kadia TM, Jabbour EJ, Nazha A, Borthakur G, Faderl S, Quintas-Cardama A, Daver NG. Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. ASH Annual Meeting 2012, 2012.
Romo CG, Kantarjian HM, Luthra R, Quintas-Cardama, Jabbour EJ, Borthakur G, Kadia TM, Ravandi F, Pemmaraju N, Pierce SA, O'Brien S, Cortes JE. Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 vs. b2a2 Fusion Transcripts. ASH Annual Meeting 2012, 2012.
Quintas-Cardama A, Kantarjian HM, Ravandi F, Foudray C, Pemmaraju N, Kadia TM, Borthakur G, Daver NG, Faderl S, Jabbour E, Cortes JE, Garcia-Manero G. Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. ASH Annual Meeting 2012, 2012.
Ohanian M, Alattar ML, Estrov Z, Quintas-Cardama A, Manning JT, Ravandi F, Abruzzo LV, Cortes JE, Pemmaraju N. Myeloid Sarcoma of the Orbit and Ocular Adnexae. ASH Annual Meeting 2012, 2012.
Ghanem H, Kantarjian HM, Jabbour E, Katragadda L, Cortes JE, Pemmaraju N, Quintas-Cardama A. Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience. ASH Annual Meeting 2012, 2012.
Hoehn D, Medeiros LJ, Pemmaraju N, Sireci A, Bhagat G, Cortes JE, Bueso-Ramos CE. Dasatinib Therapy Affects Bone Homeostatis in Patients with Chronic Myelogenous Leukemia in Chronic Phase Independently of Molecular Response. ASH Annual Meeting 2012, 2012.
Pemmaraju N, Thomas DA, Kantarjian H, O'Brien SM, Daver NG, Nazha A, Pierce S, Garcia-Manero G, Cortes JE, Faderl S. Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN). American Society of Clinical Oncology Annual Meeting, 2012.
Kadia TM, Jabbour E, Pemmaraju N, Faderl S, Borthakur G, Thomas DA, Daver NG, Ravandi F, Kantarjian H. Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). American Society of Clinical Oncology Annual Meeting 2012, 2012.
Daver NG, De Lima MJG, Kantarjian H, Ravandi F, Bilen MA, Pierce S, Khouri IF, Dorkhom SJ, Giralt S, Garcia-Manero G, Nazha A, Mathisen M, Pemmaraju N, Cortes JE, Faderl S, Jabbour E. Allogenic stem cell transplant (ASCT) as initial salvage for patients (pts) with acute myeloid leukemia (AML) refractory to high-dose cytarabine-based induction chemotherapy. American Society of Clinical Oncology Annual Meeting 2012, 2012.
Bhamidipati PK, Daver NG, Kantarjian H, Pierce S, Daver R, Cortes JE, Ravandi F, Mathisen M, Pemmaraju N, Nazha A, Kadia TM, Jabbour E, Borthakur G, Faderl S, Garcia-Manero G. FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). American Society of Clinical Oncology Annual Meeting 2012, 2012.
Hoehn D, Pemmaraju N, Cortes JE, Wang X, Kanagal-Shamanna R, Dellasala SE, Nazha A, Kantarjian HM, Medeiros LJ, Bueso-Ramos CE. Dasatinib Affects Bone Homeostasis, Independent of Molecular Response, in Patients with Chronic Myelogenous Leukemia (CML). Canadian Academy of Pathology's 101st Annual Meeting, 2012.
Pemmaraju N, Kantarjian HM, O'Brien S, Kadia TM, Cortes JE, Borthakur G, Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Quintas-Cardama A, Jabbour EJ, Koller CA, Dellasala SE, Pierce SA, Burton EM, Verstovsek S. Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia. ASH Annual Meeting 2012, 2012.
Pemmaraju N, Kantarjian HM, Tran KM, Kazmi SM, Kadia TM, Borthakur G, Verstovsek S, O'Brien S, Garcia-Manero G, Estrov Z, Faderl S, Ravandi F, Pierce SA, Cortes JE, Quintas-Cardama A. Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML). ASH Annual Meeting 2012, 2012.
Pemmaraju N, Thomas D, Kantarjian HM, Cortes JE, Manning JT, Medeiros LJ, O'Brien S, Daver NG, Nazha A, Pierce SA, Garcia-Manero G, Jabbour EJ, Faderl S. Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. ASH Annual Meeting 2012, 2012.
Pemmaraju N, Kantarjian HM, Cortes JE, Quintas-Cardama A, Pierce SA, Verstovsek S. Incidence and Outcomes of Myeloproliferative Neoplasms (MPN) in Adolescents and Young Adults (AYAs). ASH Annual Meeting 2012, 2012.
Pemmaraju N, Ravandi F, Rondon G, Giralt S, Chen J, Pierce S, Champlin R, DeLima M, Qazilbash M. Analysis of outcomes in patients (pts) with relapsed/refractory acute promyelocytic leukemia (APL) treated with and without high-dose chemotherapy and hematopoietic stem cell transplantation (HCT). Journal of Clinical Oncology 29(15):Abstr 6608, 2011.
Kadia T, Garcia-Manero G, Kantarjian H, Pemmaraju N, Stein K, Teng A, Cortes J. Retrospective analysis of effects of transfusion status on response to decitabine and survival in patients with myelodysplastic syndromes. Journal of Clinical Oncology 29(15):Abstr 6608, 2011.
Pemmaraju N, Kantarjian H, Tanaka MF, O'Brien S, Jabbour E, Quintas-Cardama A, Borthakur G, Ravandi F, Verstovsek S, Burton E, Walker B, Cortes J. Memory impairment in chronic phase chronic myeloid leukemia patients treated with dasatinib tyrosine kinase inhibitor therapy. American Society of Hematology Annual Meeting 2011, 2011.
Pemmaraju N, Kantarjian H, Luthra R, O'Brien S, Jabbour E, Quintas-Cardama A, Borthakur G, Ravandi F, Verstovsek S, Burton E, Walker B, Cortes J. Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia in chronic phase. American Society of Hematology Annual Meeting 2011, 2011.
Gushiken F, Vo YD, Xiao L, Kadia T, Cortes JE, Pemmaraju N, Pierce S, Kantarjian H, Borthakur G. Coagulation profile as prognostic indicator in acute myeloid leukemia. American Society of Hematology Annual Meeting 2011, 2011.
Takahashi K, Kantarjian H, Pemmaraju N, Borthakur G, Faderl S, Garcia-Manero G, Andreeff M, Pierce S, Ravandi F, Cortes J. FLT3 inhibitors are promising salvage therapy for relapsed or refractory acute myeloid leukemia in patients with FLT3-ITD mutations. American Society of Hematology Annual Meeting 2011, 2011.
Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults (AYA) with chronic myeloid leukemia (CML) treated with upfront tyrosine kinase inhibitors (TKI). Blood 116(21):Abstr 1234, 2010.
Pemmaraju N, Kantarjian H, Garcia-Manero G, Faderl S, Ferrajoli A, Borthakur G, Kadia T, Cortes J. Phase I study results of gimatecan in the treatment of myelodysplastic syndrome (MDS). Blood 116(21):Abstr 1883, 2010.
Pemmaraju N, Kantarjian H, O'Brien S, Verstovsek S, Jabbour E, Quintas-Cardama A, Garcia-Manero G, Borthakur G, Ravandi F, Shan J, Cortes J. Seven-year follow-up data on sequential prospective trials of imatinib 400mg vs 800mg daily schedule for front-line treatment of chronic myeloid leukemia (CML). Blood 116(21):Abstr 3438, 2010.
Pemmaraju N, Kantarjian H, Faderl S, Garcia-Manero G, Kadia T, Borthakur G, Cortes J, Ravandi Kashani F. Impact of neutropenia on the outcome of decitabine (DAC) treatment in patients (pts) with myelodysplastic syndrome (MDS). Journal of Clinical Oncology 28(15):Abstr 6605, 2010.
Pemmaraju N, Kantarjian H, Ravandi F, Garcia-Manero G, Borthakur G, Parikh S, Konopleva M, Kornblau S, Andreeff M, O'Brien S, Cortes J. FLT3 inhibitor therapy for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): impact on survival according to FLT3 status. Blood 114:Abstr 1026, 2009.
Pemmaraju N, Kantarjian H, Ravandi F, O'Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J. Acute myeloid leukemia (AML) in adolescents and young adults (AYA): The M. D. Anderson Cancer Center (MDACC) experience. Journal of Clinical Oncology 27(15):Abstr 7051, 2009.
Pemmaraju N, Kantarjian H, Ravandi F, O’Brien S, Wierda W, Thomas D, Garcia-Manero G, Borthakur G, Pierce S, Cortes J. Acute myeloid leukemia in adolescents and young adults (AYA): The MD Anderson Cancer Center (MDACC) experience. Blood 112:Abstr 3982, 2008.
Stein B, Williams D, Rogers O, Isaacs M, Pemmaraju N, Moliterno A. Gender is a phenotypic modifier in the JAK2 V617F-positive MPD. Blood 112:Abstr 1761, 2008.

Book Chapters

Pemmaraju N, Cortes J. FLT3-ITD. Clinical (Sorafenib/AC220). In: Targeted Therapy of Acute Myeloid Leukemia, 2015.
Pemmaraju N, Garcia-Manero G, Ravandi F. Methylation in AML-Clinical Applications. In: Targeted Therapy of Acute Myeloid Leukemia, 2015.
Kainthle R, Kadia T, Pemmaraju N. Leukemia. In: Handbook of Targeted Therapy. Springer, 2015.
Pemmaraju N, Parikh S, Jabbour E, Kantarjian H, Cortes J. Chronic Myeloid Leukemia. In: MD Anderson Manual of Oncology. 2nd, 2011.

Less

CV information above last modified July 11, 2024

Naveen Pemmaraju, M.D.

About Dr. Pemmaraju

In the News

ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis

Understanding the types of leukemia

Reflections on caring for cancer patients during the COVID-19 pandemic

New blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment improves outlook for many patients

Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies

Acute myeloid leukemia: What to know

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Other Articles

Abstracts

Book Chapters

Patient Reviews

Related Links

Department of Leukemia

Division of Cancer Medicine

Help #EndCancer

Naveen Pemmaraju, M.D.

About Dr. Pemmaraju

In the News

ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis

Understanding the types of leukemia

Reflections on caring for cancer patients during the COVID-19 pandemic

New blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment improves outlook for many patients

Investigational drug shows promising results in Phase II study of aggressive, often fatal blood disorder with no approved therapies

Acute myeloid leukemia: What to know

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Other Articles

Abstracts

Book Chapters

Patient Reviews

Request an Appointment

Related Links

Department of Leukemia

Division of Cancer Medicine

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer